Moderna Inc. MRNA, -0.05% said in a letter to shareholders disclosed Tuesday, Chief Executive Stéphane Bancel said the biotechnology company had shipped about 800 million doses of its COVID-19 vaccine to more than 60 countries in 2021, and more than tripled the amount of cash and cash equivalents it held. Meanwhile, the stock dropped 1.2% in premarket trading, after dropping 7.5% on Monday, and tumbling 27.9% in December. Bancel said the company had more than $17 billion in cash and cash equivalents at the end of 2021, after entering the year with about $5.25 billion. The company said it was working with the U.S. Food and Drug Administration to have its COVID-19 vaccine authorized for 12 to 17 year olds, as it is already authorized in more than 10 countries and the European Union. Separately, Bancel said Moderna’s flu vaccine has showed “positive” interim Phase 1 data, its vaccine for respiratory syncytial virus (RSV) moved to a Phase 2/3 trial and that its Personalized Cancer Vaccine Phase 2 trial is fully enrolled with a readout expected as early as the fourth quarter of 2022. The stock has dropped 27.9% over the past three months through Monday, but was still up 110.4% over the past 12 months, while the S&P 500 SPX, +0.41% has gained 11.5% the past three months and rallied 29.6% the past year.
View Article Origin Here
